China-based Doma Biopharmaceutical (Suzhou) Co., Ltd announced receiving clinical approval from the National Medical Products Administration (NMPA) for its Category 1 drug DM002. This marks a significant milestone in the development of the company’s innovative bispecific antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 3 (HER3) and mucin 1 (MUC1).
Preclinical Success and Global Expansion
DM002 has demonstrated robust anti-tumor activity and good safety in pre-clinical studies. The drug has previously obtained clinical approval in Australia and the United States, highlighting its potential as a promising therapeutic option in oncology.-Fineline Info & Tech
Leave a Reply